Spots Global Cancer Trial Database for Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies

Official Title: Development of a Microsampling Approach for Personalized Monitoring of Kinase Inhibitor Targeted Therapies

Study ID: NCT05598788

Conditions

Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

Interventions

Measurement of drug concentrations

Study Description

Brief Summary: The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.

Detailed Description: The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib. Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.